FDA Policy Power Challenged In House Questions On Untitled Letters

Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee examines whether FDA use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.

House Oversight and Investigations Subcommittee Chairman Tim Murphy is discouraging FDA from using untitled letters as instruments for communicating new policies.

Citing concerns about inconsistent practices for issuing and publicizing the letters, Murphy sent a letter to FDA May...